The invention relatesto engineered antibodies whichspecifically bind to integrin receptors,especially the alpha V integrin receptorsubunit. The antibodies comprisethe antigen binding sites (CDRs) of aknown mouse anti-integrin antibody,as well as hybrid light chain variablesequences, mutated heavy chainvariable sequences (Frs) and modifiedheavy chain constant sequences.The novel antibodies have improvedimmunogenic and expression propertiesand elicit excellent anti-angiogenic aswell as anti-tumor activities in humansin monotherapy but also and above allin combination with other angiogenesisand tumor inhibiting agents.
